What is the One-Way Heart Assist Valve?

IndieGoGo Video

How It Works

Demonstration

The One Way Heart Assist Valve can change lives and save lives.

Heart disease is the number one killer in the world.  Every year over 5 million Americans are diagnosed with Heart Valve Disease (HVD), one of the deadliest forms of heart disease. HVD can go undetected for years manifesting itself through a slow onset of symptoms like weight gain, fatigue, ongoing flu-like symptoms, shortness of breath, fluid retention, weakness and even death.

Untreated HVD often leads to Congestive Heart Failure (CHF), a condition where the heart begins to enlarge to compensate for its lack of efficiency. CHF typically creates a vicious cycle where the enlarging heart makes the valves leak more, causing the heart to enlarge more which makes the valves leak more again. Eventually, in most cases, major open-heart surgery is needed to either replace the heart (a transplant) or replace the heart valves with either mechanical valves or animal heart valves. 

Traditional valve replacement surgery can be life-saving; however, it is dangerous, invasive, time consuming, costly, and painful. In addition, the heart itself is damaged and weakened from being tampered with. Generally, heart valve replacement/repair surgery requires opening the chest, cutting the breastbone/sternum in half, and stopping the heart so the valves inside the heart can be cut out and replaced. Unfortunately, these replacements only last an average of 10 years and can rarely be done more than twice in a patient. For those with congenital heart abnormalities, this prognosis is very disheartening. 

For patients with hearts too weak for valve replacement surgery, a heart transplant may be their only option. In the United States alone, approximately 2,000 people each year get a heart transplant, but almost 200,000 people need one. This leaves 198,000 living with poor health and a decreased quality of life with essentially no alternative. For the lucky 1% who do receive a heart transplant, they must constantly battle to stay healthy.

Our One-Way Heart Assist Valve is a safer, less invasive and less expensive alternative to heart surgery that may cure over 70% of HVD cases. This option can give life and hope to hundreds of thousands of men and women living with compromised hearts.
The One-Way Heart Assist Valve is an accessible alternative to anyone suffering from HVD and is an incredible option for those who lack insurance or private funds, who have diminished health, or who have cancer or other serious diseases.

The One-Way Heart Assist Valve is a valve that can be inserted either upstream or downstream from the heart when a person has a leaky (regurgitating) valve inside their heart. Because fluid doesn’t easily compress, the valves do not need to be placed right in the heart to be effective which eliminates the need for costly and risky surgery.

Statistics say that at some point you or someone you love will be affected by valvular heart disease or congestive heart failure. This disease can be cured. The One-Way Heart Assist Valve is nothing short of a simple, inspired, solution.
To make this prototype a reality, we need your help! Browse our site, watch the videos, educate yourself on HVD, DONATE, then pass our message along to help make this miraculous procedure available before one more person has to live a diminished life because of HVD.

Technical Details:

Approximately 23 million people worldwide are afflicted with congestive heart failure (“CHF”) and two (2) million new cases of CHF are diagnosed each year worldwide. In contrast to other cardiovascular disorders that have actually declined during the past few decades, the incidence of CHF is currently on the rise. In fact, CHF is one of the most rapidly growing cardiovascular disorders in the United States.

CHF is a chronic inability of the heart to either: a) maintain an adequate output of blood from one or both ventricles of the heart to meet the metabolic demands of the tissues, or; b) adequately circulate blood in one direction through the body, without back flow, (also known as regurgitation).

In a case of CHF, the left ventricle, the right ventricle or both the left and right ventricle generally are weakened such that the volume of blood the heart is able to move may be insufficient for the patient’s body. Similarly, if the valves of the heart are leaking (e.g., allowing some blood to regurgitate or flow backwards), fluid may build up behind the heart. With a weakened left ventricle or right ventricle or both, significant problems may occur.

For example, with a weakened left ventricle or right ventricle or both, there is a shift of large volumes of blood from the systemic circulation flow into the pulmonary (lung) circulation flow. If the inability to move the volume of blood forward is due to a left heart side problem (without the right side failing as well), blood continues to be pumped into the lungs by the normal right heart side, while the blood is not pumped adequately out of the lungs by the left heart side. As the volume of blood in the lungs increases, the pulmonary vessels enlarge, pulmonary venous congestion develops, and, once the pulmonary capillary pressure rises above a critical point, fluid begins to filter out of the capillaries into the lung’s interstitial spaces and alveoli (air sacs in the lungs where exchange of oxygen and carbon dioxide occurs). Such conditions generally result in pulmonary edema and may subsequently lead to pleural effusion and abdominal effusion.

If the abnormality lies in the right heart side or the pulmonary arteries, this condition limits the ability to move blood forward (e.g., the flow of blood to the rest of the body). During this condition, congestion occurs behind the right heart side (causing pleural effusion and/or build up of fluid in the abdomen). If the left side heart valve allows fluid to regurgitate (flow backwards, upon contraction of the heart), this condition may cause the kidneys and liver to fail, due to fluid build-up therein, and excessive pressure as fluid pressurizes in those organs instead of simply flowing through them. Ultimately, if the patient has a weakened left ventricle or right ventricle or both, the patient will, over time, require a heart transplant and/or will die.

CHF is often caused by a lower non-functioning valve within the heart. CHF also causes valves that may be working properly to stop working properly as the heart increases in size to compensate for its lack of efficiency. As the heart becomes inefficient, the body compensates by increasing the size of the heart which often causes the heat valves to leak. Moreover, as the heart increases in size, the heart grows into the pericardium (which is the sac covering the heart). This condition may cause the pericardium to inflame. At the same time, when the heart expands, it begins to work excessively hard and cannot expand and contract as it needs to. Thus, the expanding heart further makes treatment of CHF difficult.

When treating CHF, drugs are typically given to the patient which cause the patient’s heart to beat harder. Alternatively, the drugs cause a thickening or thinning of the blood. While these drugs may help individual patients, they generally do not provide a long-term solution for the patient’s heart problems. Accordingly, a second treatment given to the patient may involve invasive surgery, wherein the chest is cut open and a new valve (either artificial or biological) is installed to replace the old (natural) valve, or the natural valve is repaired. A third solution involves a valve replacement similar to the second solution but does so less intrusively, by going through smaller holes and performing the surgery endoscopically. The last and most costly treatment of CHF is a full-blown heart transplant for the patient. Of course, heart transplants are prohibitively expensive and there is currently a shortage of heart donors. After a patient receives a heart transplant, drugs are required to suppress the immune system of the patient to prevent the patient's immune system from attacking the new heart. This presents an entirely new set of potential problems for the transplant patient, with respect to the patient's suppressed immune system.

Because all of the valve replacement solutions require the heart to be cut open, they are very damaging to the heart itself. This means that patients with an extremely weak heart oftentimes cannot survive this type of surgery, even if such a surgery would be otherwise beneficial. If a doctor deems a patient too weak to survive the surgery, the doctor will generally abstain from performing the valve surgery and put a patient on the “waiting list” to receive a heart transplant. Because of the lack of available transplant hearts, and the weakness of the patients awaiting these hearts, many patients die before they have a chance to receive a transplant. Although advances in pharmacology have led to better treatment, 50% of the patients with the most advanced stage of CHF generally die within one year. Traditional surgical procedures may try and repair the heart valve, but generally work by removing the native heart valve and a new valve is added to the patient. Such procedures still require the patient’s heart valves or other valves to be removed, and thus involve difficult and dangerous surgeries.

Heart valve surgery is very intrusive and therefore another solution is needed wherein the heart itself does not have to be cut open.

This is why we have developed the One-Way Heart Assist Valve. The principle is very simple. Because fluid doesn’t easily compress, one-way valves can be placed upstream and/or downstream from the heart, and the function is very similar to having a good valve inside the heart, but the heart itself remains untouched. Multiple instances of our new valves may be used in several veins/arteries to help make the heart very efficient again. The pressures and stresses on the arterial and vein walls will increase between our One-Way Heart Assist Valve and the heart. To address this issue we have created a patent pending sleeve and/or stent that can be placed between our valve and the heart.vein.

About the Inventor

Bret Park, is a Mechanical Engineer, Inventor/Entrepreneur, founder/CEO and chief engineer of DPS. Bret is an expert in fluid dynamics and turbine design and holds several patents related to automotive, medical, drilling, and fluid dynamics. Bret also has an extensive background in manufacturing and a successful history of taking products from concept to market.

Bret has designed automotive technology for over 21 years and has spent the last decade designing, inventing, and conducting research and development in the turbine industry. Much of his research focuses on the natural science of fluids in motion. By integrating his expertise in fluid dynamics and turbine design with medical science, Bret was able to develop his patent pending One-Way Heart Assist Valve.

The One-Way Heart Assist Valve was first conceived in hopes of saving Bret’s beloved father, John, and many other family members who have been diagnosed with and/or died of heart valve disease. After his father’s death, Bret was inspired to take the necessary steps to develop a product that would prevent millions of others from the pain his father and their family had to go through.